Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 7;19(1):41.
doi: 10.1186/s11671-024-03985-y.

Targeting triple negative breast cancer stem cells using nanocarriers

Nagasen Dasari  1   2   3 , Girija Sankar Guntuku  4 , Sai Kiran S S Pindiprolu  5   6
Affiliations
Review

Targeting triple negative breast cancer stem cells using nanocarriers

Nagasen Dasari et al. Discov Nano. .

Abstract

Breast cancer is a complex and heterogeneous disease, encompassing various subtypes characterized by distinct molecular features, clinical behaviors, and treatment responses. Categorization of subtypes is based on the presence or absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), leading to subtypes such as luminal A, luminal B, HER2-positive, and triple-negative breast cancer (TNBC). TNBC, comprising around 20% of all breast cancers, lacks expression of ER, PR, and HER2 receptors, rendering it unresponsive to targeted therapies and presenting significant challenges in treatment. TNBC is associated with aggressive behavior, high rates of recurrence, and resistance to chemotherapy. Tumor initiation, progression, and treatment resistance in TNBC are attributed to breast cancer stem cells (BCSCs), which possess self-renewal, differentiation, and tumorigenic potential. Surface markers, self-renewal pathways (Notch, Wnt, Hedgehog signaling), apoptotic protein (Bcl-2), angiogenesis inhibition (VEGF inhibitors), and immune modulation (cytokines, immune checkpoint inhibitors) are among the key targets discussed in this review. However, targeting the BCSC subpopulation in TNBC presents challenges, including off-target effects, low solubility, and bioavailability of anti-BCSC agents. Nanoparticle-based therapies offer a promising approach to target various molecular pathways and cellular processes implicated in survival of BSCS in TNBC. In this review, we explore various nanocarrier-based approaches for targeting BCSCs in TNBC, aiming to overcome these challenges and improve treatment outcomes for TNBC patients. These nanoparticle-based therapeutic strategies hold promise for addressing the therapeutic gap in TNBC treatment by delivering targeted therapies to BCSCs while minimizing systemic toxicity and enhancing treatment efficacy.

Keywords: Anti-BSCS agents; Breast cancer stem cells; Molecular targets; Nano carriers.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The role of cancer stem cells in Tumour recurrence & Transmission. A Conventional therapy for elimination of non-tumour stem cells & stem cells and results in tumour relapse; B The activation of transcription factors, for epithelial-to-mesenchymal transition (EMT), in BCSCs or metastatic cells. This phenotypic change facilitates their dissemination and migration. Cells undergoing EMT acquire the ability to enter the bloodstream, evading immune surveillance, and eventually reach target organs. Once in the specific organ site, these cells can enter a Inactive state that can last for months to decades. Alternatively, they can endure mesenchymal-to-epithelial transition (MET), reverting back to an epithelial state, and initiate the growth of secondary tumors. C Essential Signaling Pathways Associated with the Survival of BCSCs [14]
Fig. 2
Fig. 2
Therapies Against TNBC
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Trayes KP, Cokenakes SEH. Breast cancer treatment. Am Fam Physician. 2021;104(2):171–178. - PubMed
    1. Cox TR. The matrix in cancer. Nat Rev Cancer. 2021;21(4):217–238. doi: 10.1038/s41568-020-00329-7. - DOI - PubMed
    1. Roy M, Biswas J, Datta A. Genetics and Epigenetics of Breast Cancer. 1. Singapore: Springer; 2023. p. 87.
    1. Curigliano G, Burstein HJ, Gnant M, Loibl S, Cameron D, Regan MM, Denkert C, Poortmans P, Weber WP, Thürlimann B. St Gallen Consensus Conference Panelists 2023. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol. 2023;34(11):970–986. doi: 10.1016/j.annonc.2023.08.017. - DOI - PubMed
    1. Ye F, Dewanjee S, Li Y, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22:105. doi: 10.1186/s12943-023-01805-y. - DOI - PMC - PubMed

LinkOut - more resources